Professor Stephen Nicholls, Monash University, Clayton, Australia, reports Phase 1 data on the once daily, oral Lp(a) lowering, small molecule, muvalaplin, which disrupts the interaction between apo(a) and apoB, and discusses the design of the Phase 2 KRAKEN trial.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.